$ACHN Company News In focus: New highs premature? 9:03

New Post Public Reply Private Reply Replies (0) Message Board

Jul 3, 2014 at 12:04 PM

$ACHN Company News

In focus: New highs premature? 9:03 p.m. June 18, 2014 - Lawrence G. McMillan
Achillion shares up; FDA lifts hold on hepatitis C drug 10:25 a.m. June 10, 2014 - Anna Prior
U.S. stock futures sink on shutdown fears 8:38 a.m. Sept. 30, 2013 - Barbara Kollmeyer
Zynga shares rise, Achillion drops after hours 5:51 p.m. July 1, 2013 - Wallace Witkowski
FDA puts Achillion Hep C drug on clinical hold 5:16 p.m. July 1, 2013 - MarketWatch.com
Five stocks making moves 3:12 p.m. Feb. 14, 2013 - The Trading Deck
Thursday’s top gaining & declining stocks 5:02 p.m. Sept. 27, 2012 - Greg Morcroft
Achillion sees progress in hepatitis C study 9:04 a.m. Sept. 27, 2012 - MarketWatch.com
Vertex to advance testing of oral HCV drug regimen 10:34 a.m. Sept. 25, 2012 - Val Brickates Kennedy
Wednesday’s biggest gaining and declining stocks 4:37 p.m. Sept. 19, 2012 - MarketWatch
Achillion, Idenix move on price target changes 10:29 a.m. Sept. 19, 2012 - Val Brickates Kennedy
Gilead boosted as analysts hike price targets 10:42 a.m. Sept. 17, 2012 - Val Brickates Kennedy
Thursday’s biggest gaining and declining stocks 4:47 p.m. Aug. 16, 2012 - MarketWatch
Idenix plunges 30% on HCV drug setback 12:56 p.m. Aug. 16, 2012 - Val Brickates Kennedy
Bristol’s bad news is good for rivals: analysts 5:52 p.m. Aug. 2, 2012 - Val Brickates Kennedy
Gilead shares boosted by Bristol-Myers drug news 11:24 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Bristol-Myers falls 7% on hepatitis C drug setback 10:09 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Stocks to watch Thursday: Annie’s, Rite Aid 5:02 p.m. June 6, 2012 - David B. Wilkerson
Achillion's chief medical officer resigns 4:19 p.m. June 6, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 4:23 p.m. May 21, 2012 - MarketWatch

Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline 8:39 a.m. Today - benzinga.com
Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly 2:49 p.m. June 27, 2014 - benzinga.com
InsiderInsights.com Daily Round Up: 6/24/14 8:37 a.m. June 25, 2014 - Seeking Alpha
Achillion Could Win Idenix's Mystery Suitor: Analyst 11:44 a.m. June 20, 2014 - Investors Business Daily
Baird Comments On Achillion's Bullish Share Action 11:12 a.m. June 20, 2014 - benzinga.com
Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms 10:25 a.m. June 20, 2014 - Seeking Alpha
Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog 10:33 a.m. June 18, 2014 - Zacks.com
Benzinga's Top #PreMarket Losers 7:12 a.m. June 18, 2014 - benzinga.com
Hepatitis C May Give A Big Boost To These Drug Stocks - If The FDA Approves 1:32 p.m. June 17, 2014 - Seeking Alpha
Achillion Set to See Shares Soar 7:44 a.m. June 17, 2014 - Barrons.com
Benzinga's Top #PreMarket Losers 7:18 a.m. June 17, 2014 - benzinga.com
Maxim's $22 Price Target On Achillion Is Far From Realistic 3:33 a.m. June 17, 2014 - Seeking Alpha
If Achillion Was Going To Be Taken Out At A Big Premium, Baupost Would Probably Own It 5:56 p.m. June 16, 2014 - Seeking Alpha
Why Achillion Pharmaceuticals (ACHN) Is Spiking Today 10:33 a.m. June 16, 2014 - TheStreet.com
Achillion Gets Massive Price Target Hike On HCV Drugs 10:27 a.m. June 16, 2014 - Investors Business Daily
Maxim Group Significantly Raises Achillion's PT, Shares Soar +15% 8:34 a.m. June 16, 2014 - benzinga.com
Mid-Afternoon Market Update: Markets Reverse Early Loses; Oil Continues To Rise On Overseas Worry 2:36 p.m. June 13, 2014 - benzinga.com
Mid-Morning Market Update: Markets Mostly Flat; Priceline To Acquire OpenTable For $103/Share 9:25 a.m. June 13, 2014 - benzinga.com
Morning Market Losers 8:44 a.m. June 13, 2014 - benzinga.com
Benzinga's Top #PreMarket Losers 7:12 a.m. June 13, 2014 - benzinga.com

Achillion Pharmaceuticals Added to the Russell 2000 and Russell Microcap Indexes 4:06 p.m. July 1, 2014 - GlobeNewswire
Critical Alerts For Bank of America, Achillion Pharmaceuticals, Walmart, SunEdison, and Advanced Micro Devices Released By InvestorsObserver 9:31 a.m. June 17, 2014 - PR Newswire - PRF
If Achillion Pharmaceuticals (NASDAQ: ACHN) Investors Are Hoping for a Buyout, This is Not an Investment Strategy; Analyst Report by BrokerBank Securities, Inc. 7:00 a.m. June 13, 2014 - PR Newswire - PRF
Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos 5:20 a.m. June 12, 2014 - PR Newswire - PRF
Achillion to Present at Two Upcoming Investor Conferences 6:06 a.m. June 11, 2014 - GlobeNewswire
Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV 6:06 a.m. June 10, 2014 - GlobeNewswire
Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma 8:10 a.m. June 6, 2014 - PR Newswire - PRF
Biotech Equities Under Review -- Research on Achillion Pharma, Mast Therapeutics, Alkermes, and Momenta Pharma 1:30 p.m. May 9, 2014 - PR Newswire - PRF
Achillion Reports First Quarter 2014 Financial Results 6:06 a.m. May 7, 2014 - GlobeNewswire
Achillion to Present at Three Upcoming Investor Conferences 6:31 a.m. May 1, 2014 - GlobeNewswire
Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV 4:07 p.m. April 30, 2014 - GlobeNewswire
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys 8:16 a.m. April 14, 2014 - PR Newswire - PRF
Morning Analysis on Top Gainers -- Research on Achillion Pharma, Microvision, Miller Energy Resources, and Bon-Ton Stores 11:24 a.m. March 25, 2014 - PR Newswire - PRF
Achillion Announces Oral Presentations Given at APASL 2014 Detailing Clinical Activity of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV 6:05 a.m. March 14, 2014 - GlobeNewswire
Achillion Reports 2013 Fourth Quarter and Year-End Financial Results 7:05 a.m. March 7, 2014 - GlobeNewswire
Achillion to Present at Two Upcoming Investor Conferences 7:00 a.m. Feb. 10, 2014 - GlobeNewswire
Stock Price Movements, FDA Applications, Appointments, and Clinical Study Updates - Research Report on Alere, ARCA, Achillion, Idenix Pharmaceuticals, and Receptos 9:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones 7:25 a.m. Jan. 13, 2014 - GlobeNewswire
ACHILLION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Achillion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ACHN 12:53 p.m. Dec. 6, 2013 - PR Newswire
Increased Quarterly Dividends, HIV Elimination Efforts, Advanced Treatment Options, and Conference Participations - Research Report on Merck, Varian, Mylan, Achillion, and Abiomed 9:00 a.m. Dec. 4, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lawyers Juggle AI's Promise and Perils in 2026

AI's Growing Pains in the Legal Arena Looks like the legal eagles are getting a run for their money with AI entering the courtroom. Bloomberg Law's 2026 AI in Practice report dives deep into this legal labyrinth. You got attorneys leaning on AI to keep the gears turning, but they're also clutching their pearls over potential pitfalls. Trust Issues: Humans vs. Machines The...

Siemens Set to Acquire Lauterbach in Strategic Move

Siemens Seizing New Opportunities with Lauterbach Acquisition Bam! Siemens is on the move, folks, snapping up Lauterbach to bolster its semiconductor design arsenal. Now, if you’ve got your eyes glued to innovation in chip design, like yours truly, then strap in because this merger is more than just a footnote on some dusty tech page. It's a game-changer when it comes...

Jinko Solar Joins B20 Summit: Energy Forefront Focus

Jinko Solar's Invitation to the B20 Summit Never a dull moment in the solar space, especially when Jinko Solar, a big shot in clean energy, jumps into the spotlight at the B20 Summit in the U.S. Awash with high-profile discussions, Jinko's not just chatting—it's the only photovoltaic firm strutting its stuff in D.C. with gutsy calls for energy reform. Key Takeaways from...

Paulex Bio's Grant Fuels Bold Diabetes Research Push

Cracking the Diabetes Code: A New Hope Emerging It ain't every day you hear about a biotech outfit snagging an NIH Fast-Track grant with the potential to upend diabetes treatment, but Paulex Bio's recent score turns heads. Their brainchild, PAL-119, promises to tackle diabetes not by slapping a band-aid on symptoms, but by getting to the rotten core of the disease: the...

Shukla MD's New Concierge Program Boosts Patient Care

Shifting the Healthcare Paradigm Imagine a healthcare world where doctors actually have the time to listen and engage with you beyond just scribbling notes in haste. That's what's brewing over in Westchester, where Dr. Rachana and Dr. Vaishalee Shukla are putting the old-school patient-doctor relationship front and center with their Hybrid Choice concierge program. Run...

NHTSA, Ad Council Unveil New Anti-Buzzed Driving PSAs

Taking Aim at a Deadly Habit Everyone's got that gut feeling when a day-long meeting runs over or you're stuck in traffic — impatience morphed with slow burn menace. Now picture a whole campaign gunning for that vibe but in the hands of the young folks, those from 21 to 34. That's what we're talking about here, with the Ad Council and NHTSA serving up some fresh public...

Cognizant Boosts Claude AI with 25,000 Pro Workforce

Moving AI from Theory to Practice You know, AI isn't about just keeping up with the hype; it's about shoving those algorithms right where they can do the most good—right at the core of business operations. And that’s precisely what Cognizant's cooking up with their fresh-off-the-press Claude Frontier Capability Group. They’ve thrown more than 25,000 pros into the...

Bandwidth's SI Innovations: A New Dawn or Just Hype?

Bandwidth Unleashes Super Intelligence at Reverb Right off the bat, Bandwidth's Reverb showcase was enough to stir up some excitement in the air. The company laid out a feast of technological advancements with their Super Intelligence (SI) innovations that claim to redefine how enterprises communicate. But here's the rub—while these developments sound thrilling, the...

Parachute Health Urges HME Transformation Through Collaboration

The Road to Digital Unity in HME Cranking through the gears of the healthcare industry is no mean feat, but Parachute Health seems ready to throw some fresh oil on the machine. In a landscape riddled with complexities, they're sounding the call for a more unified digital infrastructure in the Home Medical Equipment (HME) sector through their latest white paper. We're...

What's at Stake: Pearl Diver's Q3 2026 Earnings Call

Upcoming Unveiling: Pearl Diver's Latest Financials Heads up, folks. November 16 can't come soon enough for those keeping tabs on Pearl Diver Credit Company Inc. (NYSE: PDCC, PDPA). The bigwigs over there are planning to spill the beans on their third quarter 2026 financial results. They'll kick things off before the market even has its first cup of java on Monday morning...